A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

NCT04868890 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
200
Enrollment
INDUSTRY
Sponsor class

Stopped The AP-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint.

Conditions

Interventions

Sponsor

Ampio Pharmaceuticals. Inc.